In recent years, the diabetes drug Ozempic has gained significant attention for its remarkable weight loss effects. However, the drug has now become a topic of heated debate due to the multitude of reported side effects, ranging from inconvenient to severe, that have compelled many patients to discontinue its use. Dr. Mark Hyman, co-founder and chief medical officer of Function, has voiced concerns about the potential health risks associated with Ozempic, highlighting that certain complications can spike by up to 900 percent.

During an episode of the podcast "The Diary Of A CEO" on April 11, Dr. Hyman shared his thoughts on Ozempic, emphasizing that the treatment is relatively new to the market. While officially approved to treat type 2 diabetes in 2017, Hyman listed several concerns, such as the cost and the likelihood of weight regain if the drug is discontinued without rigorous lifestyle changes.

"It's not a lifestyle change program. It doesn't help you change your behaviors or habits," Hyman explained, likening it to a pharmacological straight jacket. However, he acknowledged its potential benefits for individuals who are significantly overweight and want to avoid gastric bypass surgery.

One of the major issues Dr. Hyman raised was the impact of Ozempic on the body, including the loss of muscle mass, which can have negative effects on metabolism and overall health. Furthermore, he expressed alarm over the emergence of serious side effects associated with the drug, describing the side effect profile as "scary."

Hyman highlighted that the risk of bowel obstruction, a serious medical condition requiring surgical intervention, is increased by 450 percent in patients taking Ozempic. Moreover, the risk of pancreatitis, a painful condition that affects digestion and insulin secretion, was found to be elevated by a staggering 900 percent.

When questioned about the cause of these side effects, Dr. Hyman attributed them directly to the drug itself, explaining that Ozempic affects the gut by thickening the bowel wall and interfering with hormonal and metabolic functions. He also anticipated that more side effects would emerge over time, including those affecting kidney health.

In response to Hyman's comments, a spokesperson for Novo Nordisk, the manufacturer of Ozempic, emphasized that patient safety is their top priority. The company stated that they will continue to work closely with the U.S. Food and Drug Administration (FDA) to monitor the safety of all their GLP1RA drugs, including Ozempic.

Dr. Hyman, however, believes that addressing the obesity problem is the real solution. He emphasized the need for policy changes, reevaluation of agricultural and food processing systems, education, and overall societal changes to combat the issue. While acknowledging the potential benefits of Ozempic, Hyman concluded that the drug is not a risk-free solution.

As the controversy surrounding Ozempic continues, it is important to consult with healthcare professionals for personalized guidance regarding medications and any related health concerns.